Drug Trial Radar · NCT06347133
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,456
Actual
Start
May 21, 2024
Primary completion
Jun 1, 2026
Study completion Sep 8, 2026
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Conditions
- Hypertriglyceridemia
Interventions
Plozasiran InjectionDrug
ARO-APOC3 Injection
PlaceboDrug
sterile normal saline (0.9% NaCl)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to PlaceboTime frame: Baseline, Month 12
Locations
235 sites in 15 countries. Site status is shown where the registry gives one.
Research Site 1
Birmingham, Alabama
Research Site 2
Mobile, Alabama
Research Site 3
Beverly Hills, California
Research Site 4
Canoga Park, California
Research Site 5
Garden Grove, California
Research Site 6
Huntington Beach, California
Research Site 7
Lake Forest, California
Research Site 8
Lincoln, California
Research Site 9
Long Beach, California
Research Site 10
Montclair, California
Research Site 11
Oxnard, California
Research Site 12
Redding, California
Research Site 13
Van Nuys, California
Research Site 14
Colorado Springs, Colorado
Research Site 15
Clearwater, Florida
Research Site 16
Hialeah, Florida
Research Site 17
Lake City, Florida
Research Site 18
Miami Lakes, Florida
Research Site 19
Mt. Dora, Florida
Research Site 20
North Miami Beach, Florida
Research Site 21
Orlando, Florida
Research Site 22
Pensacola, Florida
Research Site 23
Sarasota, Florida
Research Site 24
Tamarac, Florida
Research Site 25
Lawrenceville, Georgia
Research Site 26
Macon, Georgia
Research Site 27
Savannah, Georgia
Research Site 28
Sugar Hill, Georgia
Research Site 29
Park Ridge, Illinois
Research Site 30
Elkhart, Indiana
Research Site 31
Indianapolis, Indiana
Research Site 32
South Bend, Indiana
Research Site 33
Overland Park, Kansas
Research Site 34
Topeka, Kansas
Research Site 35
Louisville, Kentucky
Research Site 36
Zachary, Louisiana
Research Site 37
Annapolis, Maryland
Research Site 38
Baltimore, Maryland
Research Site 39
Flint, Michigan
Research Site 40
Minneapolis, Minnesota
Showing 40 of 235 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.